Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346113 | 0.74 | EPHX2 (0.33) | ERN1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28236216 | 0.73 | KMT2A (0.40) | HTTMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2591948 | 0.71 | ERN1 (0.40) | ERN1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4312443 | 0.69 | ALDH1A1 (0.34) | — | |
| SCHEMBL17175977 | 0.69 | MEN1 (0.35) | HTTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL31342255 | 0.69 | RXRA (0.35) | — | |
| SCHEMBL17711299 | 0.69 | RXRA (0.35) | — | |
| SCHEMBL29470879 | 0.68 | KDM1A (0.33) | HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16035613 | 0.68 | KDM1A (0.33) | HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22124670 | 0.68 | MEN1 (0.32) | HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354901-A | Thiazolidinedione compound and preparation method and application thereof | 郑州大学 | 2023-06-30 | — | — | CN | claimed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | claimed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | claimed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1678146-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1678164-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005040133-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-05-06 | — | — | WO | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2005035527-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-21 | — | — | WO | claimed |
| JP-3005413-A | — | — | None | — | — | JP | disclosed |
| CN-116354901-B | Thiazolidinedione compound and preparation method and application thereof | 郑州大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-116354901-A | Thiazolidinedione compound and preparation method and application thereof | 郑州大学 | 2023-06-30 | — | — | CN | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| CN-101374844-B | Pyrrolopyridazinone compound | UBE INDUSTRIES | 2012-10-24 | — | — | CN | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005035527-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1521125-A1 | Electrophotographic photoconductor, electrophotographic method, electrophotographic apparatus, process cartridge for electrophotographic apparatus and azo compound | Ricoh Company (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-5646136-A | ADMINISTERING STEROID HAVING ANGIOSTATIC ACTIVITY TO A PATIENT | DUKE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
| JP-H035413-A | HAIR TONIC | SATO SEIYAKU KK | 1991-01-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | ERN1 1044/4885HTT 3946/4885MEN1 36/4885 |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ERN1 1244/4885HTT 4097/4885MEN1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.